<h1>Gilead Partners with Indian Pharma for Generic Hepatitis C Drugs in 91 Countries, Boosting Global Access to Treatment.</h1> A delegation from Gilead Sciences, Inc. met with India's Minister of Commerce and Industry to discuss non-exclusive licensing agreements with seven Indian generic pharmaceutical manufacturers. These agreements allow the companies to produce Sofosbuvir and a single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries, covering 54% of the global Hepatitis C-infected population. The agreements include no price limitations to encourage competitive pricing. The Minister welcomed the initiative, highlighting the importance of balancing intellectual property rights with technology transfer to enhance manufacturing capabilities and improve access to medicines through transparent licensing.